Poliwogg Aims To Disrupt Life Science Crowdfunding With A Novel Investment Model
This article was originally published in The Pink Sheet Daily
Poliwogg expects to launch its crowdfunding portal by year end to accredited investors, trusting that the JOBS Act provisions encouraging the public marketing of private offerings – enlarging the size of the investor pool, and upping the amount that private companies can raise – will provide a foundation for a sustainable business.
You may also be interested in...
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.